• Recruiting

NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM

NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma


kid study - iberdomide

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma


This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.


Sponsor

Hackensack Meridian Health

 

ClinicalTrials.gov Identifier: NCT05199311


Official Title: A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma


First Posted : January 20, 2022


Click here for details on Clinicaltrials.gov

 

Drug: Carfilzomib

Drug: Iberdomide

Drug: Oral Dexamethasone

 

Location

United States, New Jersey






Posts Archive